eGlint Joins Novelna-Led ARPA-H DELPHI Project to Advance Continuous Wearable Molecular Monitoring
Building on a successful proof-of-concept collaboration with Siomyx, eGlint will contribute its ProteoNex™ biosensing technology to next-generation wearable devices.
LA JOLLA, Calif. — October 2026 — eGlint, a biotechnology company developing next-generation molecular biosensing technologies, today announced its participation in PULSE (Proactive Unified Longitudinal Sensing Ecosystem), a Novelna-led project supported by the Advanced Research Projects Agency for Health (ARPA-H) under its DELPHI program.
PULSE brings together a multidisciplinary consortium to develop wearable biosensors capable of continuously monitoring low-abundance molecular biomarkers in interstitial fluid. The project's initial clinical focus is monitoring inflammation following heart attacks, with the broader vision of enabling continuous, personalized molecular health monitoring.
eGlint will contribute its proprietary ProteoNex™ aptamer-based biosensing technology, designed for rapid, highly sensitive detection of proteins and other molecular targets.
The collaboration builds on earlier joint feasibility work between eGlint and Siomyx, during which the companies demonstrated proof of concept integrating eGlint's ProteoCare™ biosensing technology with Siomyx's CMOS biochips. This successful pilot laid the technical foundation for their collaboration on miniaturized molecular sensing within the PULSE project.
"When ARPA-H first announced DELPHI, it almost felt as though they had written the challenge specifically for us," said Denis Malyshev, Ph.D., Co-founder and COO of eGlint. "Continuous glucose monitoring has transformed diabetes care, but many clinically important biomarkers are present at concentrations millions to billions of times lower than glucose. Measuring them continuously is an extraordinary technical challenge — and precisely the kind of problem we've been developing our technology to solve."
Malyshev added: "We're especially grateful to Siomyx team and their leader Arjang Hassibi, who recognized the potential of combining our technologies and invited us to join this remarkable consortium. Our successful pilot together gives us a great starting point. We also want to thank Ashkan Afshin and the Novelna team for bringing this ambitious vision to life, and ARPA-H for supporting innovations that push the boundaries of what's possible."
"Seeing the technology we've spent years developing at eGlint now being applied toward continuous wearable monitoring is incredibly exciting," said Adam Weisman, Head of R&D at eGlint. "We've demonstrated that our approach can enable sensitive molecular detection, including integration with CMOS biochips. Now we have the opportunity to take that work to an entirely new level — toward miniaturized devices that could continuously measure clinically meaningful biomarkers. We're thrilled to be working with this exceptional team."
The PULSE project represents an important step toward extending continuous monitoring beyond glucose and conventional physiological signals. If successful, the platform could enable earlier detection of biological changes, more personalized treatment, and improved monitoring of patients outside traditional healthcare settings.
About eGlint
eGlint is a biotechnology company developing ProteoNex™, an aptamer-based molecular biosensing platform designed for rapid, sensitive detection of proteins and other clinically relevant analytes. Its technologies span research-use assays, point-of-care diagnostics, and emerging applications in personal molecular monitoring.
Learn more at www.eglint.com.
About ARPA-H DELPHI
The DELPHI program, launched by the Advanced Research Projects Agency for Health (ARPA-H), aims to advance a new generation of modular, interoperable biosensing technologies for continuous monitoring of important biological signals.
Learn more:
Novelna's PULSE announcement: https://novelna.com/pr-oct-2026-pulse
This research is funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions expressed herein are those of eGlint and do not necessarily represent the official policies or positions of the U.S. Government.
